Leukapheresis – a widely used medical procedure for curing chronic lymphocytic leukemia
Leukapheresis is basically a medical procedure used to treat patients with chronic lymphocytic leukemia or those with extremely high white blood cell count. Leukapheresis is a type of test performed in apheresis. In this procedure, white blood cells are removed including leukemia cells, and return the rest of the blood cells into the bloodstream. When a patient has a leukemia attack, the immune system begins to produce antibodies that attack the leukemic cells that have invaded the body. Once these cells are eliminated, the patient begins to show signs of recovery and may even be cured by some medications. The leukapheresis process is also used in research and development activities. This procedure is mostly performed on the patient suffering from leukemia.
The growing prevalence of incidence of leukemia around the globe is a prime factor fueling the market growth of leukapheresis. According to the National Cancer Institute, the rate of new cases of leukemia was 14.1 per 100,000 men and women per year. The death rate was 6.3 per 100,000 men and women per year. In 2017, there were an estimated 434,982 people living with leukemia in the United States. High demand for blood and blood components is also projected to foster market growth. Moreover, a growing number of clinical trials for the development of CAR-T therapy for leukemia is further projected to augment the market growth of the leukapheresis.
On the other hand, the high cost associated with the treatment of leukapheresis is expected to hinder the market growth over the forecast period.
North America is expected to gain significant growth over the forecast period and this is attributed to increasing healthcare expenditure in the region. According to the U.S. Centers for Medicare & Medicaid Services, the U.S. health care spending grew 4.6 percent in 2018, reaching $3.6 trillion or $11,172 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent. Also, the high presence of chronic disease in the region is further projected to foster market growth. According to the National Health Council, chronic diseases affect approximately 133 million Americans, representing more than 40% of the total population of this country.2 By 2020, that number is projected to grow to an estimated 157 million, with 81 million having multiple conditions.
Key Developments:
In July 2020, Kite, a Gilead Company announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus™ (brexucabtagene autoleucel, formerly KTE-X19), the first and only approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
In January 2020, Fresenius Kabi inaugurates €30 million expansion of transfusion and apheresis disposables plant in the Dominican Republic. These products are used, for example, to collect blood components such as platelets or plasma.

Comments
Post a Comment